IM Cannabis Corp. (IMCC)
USD 1.73
(2.37%)
USD 1.73
(2.37%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -9.49 Million CAD | 61.89% |
| 2022 | -24.92 Million CAD | -34.58% |
| 2021 | -18.51 Million USD | 35.55% |
| 2020 | -28.73 Million CAD | -287.3% |
| 2019 | -7.41 Million CAD | -540.82% |
| 2018 | 1.68 Million CAD | 1446.72% |
| 2017 | -124.97 Thousand CAD | -693.46% |
| 2016 | -15.75 Thousand CAD | 65.47% |
| 2015 | -45.61 Thousand CAD | -21.03% |
| 2014 | -37.68 Thousand CAD | 83.5% |
| 2013 | -228.34 Thousand CAD | 95.75% |
| 2012 | -5.37 Million CAD | -933.92% |
| 2011 | -519.77 Thousand CAD | 22.33% |
| 2010 | -669.18 Thousand CAD | 49.46% |
| 2009 | -1.32 Million CAD | 6.37% |
| 2008 | -1.41 Million CAD | -85.5% |
| 2007 | -762.39 Thousand CAD | -24.7% |
| 2006 | -611.37 Thousand CAD | 26.92% |
| 2005 | -836.56 Thousand CAD | -15944.61% |
| 2004 | -5214.00 CAD | 99.22% |
| 2003 | -666.17 Thousand CAD | 34.91% |
| 2002 | -1.02 Million CAD | -17.88% |
| 2001 | -868.2 Thousand CAD | -36.14% |
| 2000 | -637.7 Thousand CAD | 29.14% |
| 1999 | -900 Thousand CAD | 50.0% |
| 1998 | -1.8 Million CAD | -63.64% |
| 1997 | -1.1 Million CAD | -22.22% |
| 1996 | -900 Thousand CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -3.02 Million CAD | 46.13% |
| 2024 Q1 | -5.62 Million CAD | -70.96% |
| 2023 Q3 | -6.2 Million CAD | -67.54% |
| 2023 Q2 | -3.7 Million CAD | -8718.6% |
| 2023 FY | -9.49 Million CAD | 61.89% |
| 2023 Q4 | -3.28 Million CAD | 47.03% |
| 2023 Q1 | 43 Thousand CAD | 100.45% |
| 2022 Q2 | -18.97 Million CAD | -76.69% |
| 2022 Q1 | -10.74 Million CAD | 16.7% |
| 2022 FY | -24.92 Million CAD | -34.58% |
| 2022 Q4 | -9.65 Million CAD | -112.95% |
| 2022 Q3 | -4.53 Million CAD | 76.12% |
| 2021 Q1 | 4.5 Million CAD | 123.27% |
| 2021 Q4 | -12.89 Million USD | -200.91% |
| 2021 Q2 | -4.63 Million CAD | -202.77% |
| 2021 FY | -18.51 Million USD | 35.55% |
| 2021 Q3 | -4.28 Million CAD | 7.45% |
| 2020 Q1 | -417 Thousand CAD | -120.11% |
| 2020 FY | -28.73 Million CAD | -287.3% |
| 2020 Q2 | -9.57 Million CAD | -2197.12% |
| 2020 Q4 | -19.35 Million CAD | -3050.91% |
| 2020 Q3 | 656 Thousand CAD | 106.85% |
| 2019 Q1 | -15.87 Thousand CAD | 15.94% |
| 2019 Q4 | 2.07 Million CAD | 220.3% |
| 2019 Q3 | -1.72 Million CAD | -391718.18% |
| 2019 FY | -7.41 Million CAD | -540.82% |
| 2019 Q2 | -440.00 CAD | 97.23% |
| 2018 Q2 | -60.98 Thousand CAD | 34.12% |
| 2018 Q4 | -18.88 Thousand CAD | -102.0% |
| 2018 Q1 | -92.57 Thousand CAD | -352.82% |
| 2018 FY | 1.68 Million CAD | 1446.72% |
| 2018 Q3 | 944 Thousand CAD | 1647.92% |
| 2017 Q3 | -10.38 Thousand CAD | -554.48% |
| 2017 FY | -124.97 Thousand CAD | -693.46% |
| 2017 Q1 | -15.75 Thousand CAD | 0.0% |
| 2017 Q2 | -1586.00 CAD | 89.93% |
| 2017 Q4 | -20.44 Thousand CAD | -96.95% |
| 2016 FY | -15.75 Thousand CAD | 65.47% |
| 2016 Q3 | - CAD | 0.0% |
| 2016 Q2 | - CAD | 0.0% |
| 2016 Q4 | - CAD | 0.0% |
| 2015 FY | -45.61 Thousand CAD | -21.03% |
| 2014 Q1 | -110.51 Thousand CAD | -186.67% |
| 2014 Q3 | -72.69 Thousand CAD | -226.67% |
| 2014 Q4 | -80.65 Thousand CAD | -10.95% |
| 2014 Q2 | -22.25 Thousand CAD | 79.86% |
| 2014 FY | -37.68 Thousand CAD | 83.5% |
| 2013 Q4 | -38.55 Thousand CAD | 19.3% |
| 2013 Q2 | -31.51 Thousand CAD | 99.39% |
| 2013 Q1 | -5.14 Million CAD | -6622.37% |
| 2013 Q3 | -47.77 Thousand CAD | -51.6% |
| 2013 FY | -228.34 Thousand CAD | 95.75% |
| 2012 Q4 | -76.58 Thousand CAD | -1.43% |
| 2012 Q1 | -120.77 Thousand CAD | -47.31% |
| 2012 Q2 | -73.43 Thousand CAD | 39.2% |
| 2012 Q3 | -75.5 Thousand CAD | -2.82% |
| 2012 FY | -5.37 Million CAD | -933.92% |
| 2011 Q4 | -81.99 Thousand CAD | 37.15% |
| 2011 Q3 | -130.45 Thousand CAD | 30.07% |
| 2011 Q2 | -186.55 Thousand CAD | 15.99% |
| 2011 Q1 | -222.06 Thousand CAD | -109.57% |
| 2011 FY | -519.77 Thousand CAD | 22.33% |
| 2010 Q4 | -105.96 Thousand CAD | 54.16% |
| 2010 Q1 | -304.61 Thousand CAD | 55.79% |
| 2010 Q2 | -109.98 Thousand CAD | 63.89% |
| 2010 Q3 | -231.17 Thousand CAD | -110.18% |
| 2010 FY | -669.18 Thousand CAD | 49.46% |
| 2009 Q4 | -689.02 Thousand CAD | -316.36% |
| 2009 Q2 | -167 Thousand CAD | 27.47% |
| 2009 Q1 | -230.24 Thousand CAD | 7.41% |
| 2009 FY | -1.32 Million CAD | 6.37% |
| 2009 Q3 | -165.48 Thousand CAD | 0.91% |
| 2008 Q4 | -248.68 Thousand CAD | -1124.28% |
| 2008 Q3 | -20.31 Thousand CAD | 97.78% |
| 2008 Q2 | -915 Thousand CAD | -813.38% |
| 2008 FY | -1.41 Million CAD | -85.5% |
| 2008 Q1 | -100.17 Thousand CAD | 6.49% |
| 2007 Q2 | -432.03 Thousand CAD | -22.31% |
| 2007 FY | -762.39 Thousand CAD | -24.7% |
| 2007 Q1 | -353.23 Thousand CAD | -311.72% |
| 2007 Q4 | -107.12 Thousand CAD | 12.99% |
| 2007 Q3 | -123.12 Thousand CAD | 71.5% |
| 2006 Q4 | -85.79 Thousand CAD | 25.79% |
| 2006 Q3 | -115.61 Thousand CAD | -103.81% |
| 2006 FY | -611.37 Thousand CAD | 26.92% |
| 2006 Q1 | -161.37 Thousand CAD | 66.85% |
| 2006 Q2 | -56.72 Thousand CAD | 64.85% |
| 2005 FY | -836.56 Thousand CAD | -15944.61% |
| 2005 Q4 | -486.75 Thousand CAD | -386.04% |
| 2005 Q3 | -100.14 Thousand CAD | -13.42% |
| 2005 Q2 | -88.29 Thousand CAD | 70.26% |
| 2005 Q1 | -296.85 Thousand CAD | -266.48% |
| 2004 Q1 | 126.09 Thousand CAD | 120.18% |
| 2004 FY | -5214.00 CAD | 99.22% |
| 2004 Q2 | -55.51 Thousand CAD | -144.03% |
| 2004 Q3 | 428.15 Thousand CAD | 871.2% |
| 2004 Q4 | -81 Thousand CAD | -118.92% |
| 2003 Q2 | -59.27 Thousand CAD | 76.17% |
| 2003 Q3 | -113.38 Thousand CAD | -91.27% |
| 2003 Q1 | -248.73 Thousand CAD | -308.24% |
| 2003 FY | -666.17 Thousand CAD | 34.91% |
| 2003 Q4 | -624.72 Thousand CAD | -450.98% |
| 2002 FY | -1.02 Million CAD | -17.88% |
| 2002 Q3 | -659.38 Thousand CAD | -1111.77% |
| 2002 Q1 | -38.54 Thousand CAD | 94.15% |
| 2002 Q4 | -60.92 Thousand CAD | 90.76% |
| 2002 Q2 | -54.41 Thousand CAD | -41.17% |
| 2001 Q4 | -659.33 Thousand CAD | -679.75% |
| 2001 Q2 | -85.75 Thousand CAD | 74.85% |
| 2001 FY | -868.2 Thousand CAD | -36.14% |
| 2001 Q1 | -340.94 Thousand CAD | -308.62% |
| 2001 Q3 | -84.55 Thousand CAD | 1.4% |
| 2000 Q1 | -500 Thousand CAD | 0.0% |
| 2000 Q4 | -83.43 Thousand CAD | 73.37% |
| 2000 Q3 | -313.32 Thousand CAD | -213.32% |
| 2000 Q2 | -100 Thousand CAD | 80.0% |
| 2000 FY | -637.7 Thousand CAD | 29.14% |
| 1999 Q3 | -200 Thousand CAD | 0.0% |
| 1999 FY | -900 Thousand CAD | 50.0% |
| 1999 Q4 | - CAD | 100.0% |
| 1999 Q2 | -200 Thousand CAD | 81.82% |
| 1999 Q1 | -1.1 Million CAD | -450.0% |
| 1998 Q3 | -400 Thousand CAD | -300.0% |
| 1998 FY | -1.8 Million CAD | -63.64% |
| 1998 Q4 | -200 Thousand CAD | 50.0% |
| 1998 Q1 | -1 Million CAD | -1100.0% |
| 1998 Q2 | -100 Thousand CAD | 90.0% |
| 1997 Q3 | - CAD | 100.0% |
| 1997 Q2 | -200 Thousand CAD | 0.0% |
| 1997 FY | -1.1 Million CAD | -22.22% |
| 1997 Q4 | 100 Thousand CAD | 0.0% |
| 1996 FY | -900 Thousand CAD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 18.77 Million USD | 150.578% |
| Aquestive Therapeutics, Inc. | -7.87 Million USD | -20.686% |
| Collegium Pharmaceutical, Inc. | 48.15 Million USD | 119.724% |
| Cosmos Health Inc. | -18.54 Million USD | 48.778% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 52.646% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 95.461% |
| Cronos Group Inc. | -73.96 Million USD | 87.158% |
| Incannex Healthcare Limited | -18.45 Million USD | 48.545% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 77.492% |
| Lifecore Biomedical, Inc. | 12.01 Million USD | 179.064% |
| Regencell Bioscience Holdings Limited | -4.3 Million USD | -120.789% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -110.784% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -110.784% |
| SCYNEXIS, Inc. | 67.04 Million USD | 114.167% |
| Safety Shot Inc | -15.08 Million USD | 37.029% |
| Theratechnologies Inc. | -23.95 Million USD | 60.354% |
| Alpha Teknova, Inc. | -36.78 Million USD | 74.176% |
| Universe Pharmaceuticals INC | -6.16 Million USD | -54.112% |
| Pacira BioSciences, Inc. | 41.95 Million USD | 122.639% |
| Sonoma Pharmaceuticals, Inc. | -4.83 Million USD | -96.443% |
| Dynavax Technologies Corporation | -6.38 Million USD | -48.662% |
| Ironwood Pharmaceuticals, Inc. | -1 Billion USD | 99.052% |
| Radius Health, Inc. | -25.79 Million USD | 63.173% |
| China SXT Pharmaceuticals, Inc. | -3.09 Million USD | -206.532% |
| Alvotech | -551.73 Million USD | 98.279% |
| Intra-Cellular Therapies, Inc. | -139.67 Million USD | 93.2% |
| SIGA Technologies, Inc. | 68.06 Million USD | 113.954% |
| Shineco, Inc. | -22.44 Million USD | 57.691% |
| Silver Spike Investment Corp. | 7.34 Million USD | 229.399% |
| Journey Medical Corporation | -3.85 Million USD | -146.509% |
| Petros Pharmaceuticals, Inc. | -8.16 Million USD | -16.352% |
| Embecta Corp. | 70.4 Million USD | 113.491% |
| Harrow Health, Inc. | -24.41 Million USD | 61.091% |
| Procaps Group, S.A. | 42.54 Million USD | 122.327% |
| Biofrontera Inc. | -20.13 Million USD | 52.819% |
| DURECT Corporation | -27.62 Million USD | 65.617% |
| PainReform Ltd. | -9.34 Million USD | -1.648% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 821.733% |
| OptiNose, Inc. | -35.48 Million USD | 73.232% |
| RedHill Biopharma Ltd. | 23.91 Million USD | 139.714% |
| Organogenesis Holdings Inc. | 4.94 Million USD | 292.073% |
| Cumberland Pharmaceuticals Inc. | -6.27 Million USD | -51.258% |
| ProPhase Labs, Inc. | -16.78 Million USD | 43.404% |
| Phibro Animal Health Corporation | 2.41 Million USD | 493.129% |
| Procaps Group S.A. | 42.54 Million USD | 122.327% |
| TherapeuticsMD, Inc. | -10.27 Million USD | 7.589% |
| Viatris Inc. | 54.7 Million USD | 117.364% |
| Rockwell Medical, Inc. | -8.43 Million USD | -12.549% |
| Aytu BioPharma, Inc. | -15.84 Million USD | 40.053% |
| Tilray Brands, Inc. | -244.98 Million USD | 96.123% |
| PetIQ, Inc. | 2.13 Million USD | 545.706% |
| Talphera, Inc. | -18.39 Million USD | 48.372% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 103.804% |
| Alimera Sciences, Inc. | -20.13 Million USD | 52.821% |
| Assertio Holdings, Inc. | -331.94 Million USD | 97.139% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6.59 Million USD | -44.068% |
| Avadel Pharmaceuticals plc | -160.27 Million USD | 94.074% |
| Hempacco Co., Inc. | -13.12 Million USD | 27.64% |
| Alvotech | -551.73 Million USD | 98.279% |
| Lantheus Holdings, Inc. | 326.66 Million USD | 102.908% |
| Kamada Ltd. | 8.28 Million USD | 214.655% |
| Currenc Group, Inc. | -15.3 Million USD | 37.948% |
| Indivior PLC | 2 Million USD | 574.9% |
| Evoke Pharma, Inc. | -7.79 Million USD | -21.89% |
| Flora Growth Corp. | -57.03 Million USD | 83.347% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 52.646% |
| Evolus, Inc. | -61.68 Million USD | 84.602% |
| HUTCHMED (China) Limited | 100.78 Million USD | 109.424% |
| Amphastar Pharmaceuticals, Inc. | 137.54 Million USD | 106.905% |
| Akanda Corp. | -32.27 Million USD | 70.572% |